OBJECTIVE: To determine the effect of a lower dose of rituximab in depleting B lymphocytes, maintaining low B-cell counts, and relapse in patients with neuromyelitis optica (NMO) and NMO spectrum disorders. METHODS: We treated 5 Chinese patients with deteriorating NMO and NMO spectrum disorders with a 100-mg IV infusion of rituximab once a week for 3 consecutive weeks, followed by additional infusion of the same dosage depending on circulating B-cell repopulation. RESULTS: This reduced dosage of rituximab was sufficient to deplete B cells and maintain low B-cell counts. None of the treated patients experienced relapse, and all patients exhibited stabilized or improved neurologic function during the 1-year follow-up period. MRI revealed the absence of new lesions, no enhancement in spinal cord and brain, a significant shrinkage of spinal cord segments, and a reduction/disappearance of previous brain lesions. CONCLUSION: A lower dosage of rituximab may be sufficient in depleting B cells, maintaining low B-cell counts, and preventing disease progression in Chinese patients with NMO.
OBJECTIVE: To determine the effect of a lower dose of rituximab in depleting B lymphocytes, maintaining low B-cell counts, and relapse in patients with neuromyelitis optica (NMO) and NMO spectrum disorders. METHODS: We treated 5 Chinese patients with deteriorating NMO and NMO spectrum disorders with a 100-mg IV infusion of rituximab once a week for 3 consecutive weeks, followed by additional infusion of the same dosage depending on circulating B-cell repopulation. RESULTS: This reduced dosage of rituximab was sufficient to deplete B cells and maintain low B-cell counts. None of the treated patients experienced relapse, and all patients exhibited stabilized or improved neurologic function during the 1-year follow-up period. MRI revealed the absence of new lesions, no enhancement in spinal cord and brain, a significant shrinkage of spinal cord segments, and a reduction/disappearance of previous brain lesions. CONCLUSION: A lower dosage of rituximab may be sufficient in depleting B cells, maintaining low B-cell counts, and preventing disease progression in Chinese patients with NMO.
Authors: Stefan Blum; David Gillis; Helen Brown; Richard Boyle; Robert Henderson; David Heyworth-Smith; Patrick Hogan; Paul Kubler; Cecilie Lander; Nicole Limberg; Peter Pillans; Kerri Prain; Christopher Staples; Michael Walsh; Pamela McCombe; Richard Wong Journal: J Neurol Neurosurg Psychiatry Date: 2010-11-11 Impact factor: 10.154
Authors: Benjamin M Greenberg; Donna Graves; Gina Remington; Paula Hardeman; Martha Mann; Nitin Karandikar; Olaf Stuve; Nancy Monson; Elliot Frohman Journal: Mult Scler Date: 2012-01-19 Impact factor: 6.312
Authors: Gurdesh S Bedi; Andrew D Brown; Sylvia R Delgado; Nida Usmani; Byron L Lam; William A Sheremata Journal: Mult Scler Date: 2011-05-26 Impact factor: 6.312
Authors: Anu Jacob; Brian G Weinshenker; Ivo Violich; Nancy McLinskey; Lauren Krupp; Robert J Fox; Dean M Wingerchuk; Mike Boggild; Cris S Constantinescu; Aaron Miller; Tracy De Angelis; Marcelo Matiello; Bruce A C Cree Journal: Arch Neurol Date: 2008-09-08
Authors: Drew Provan; Tom Butler; Maria Laura Evangelista; Sergio Amadori; Adrian C Newland; Roberto Stasi Journal: Haematologica Date: 2007-12 Impact factor: 9.941
Authors: Russell C Dale; Fabienne Brilot; Lisa V Duffy; Marinka Twilt; Amy T Waldman; Sona Narula; Eyal Muscal; Kumaran Deiva; Erik Andersen; Michael R Eyre; Despina Eleftheriou; Paul A Brogan; Rachel Kneen; Gulay Alper; Banu Anlar; Evangeline Wassmer; Kirsten Heineman; Cheryl Hemingway; Catherine J Riney; Andrew Kornberg; Marc Tardieu; Amber Stocco; Brenda Banwell; Mark P Gorman; Susanne M Benseler; Ming Lim Journal: Neurology Date: 2014-06-11 Impact factor: 9.910
Authors: Pietro Annovazzi; M Capobianco; L Moiola; F Patti; J Frau; A Uccelli; D Centonze; P Perini; C Tortorella; L Prosperini; G Lus; A Fuiani; M Falcini; V Martinelli; G Comi; A Ghezzi Journal: J Neurol Date: 2016-06-10 Impact factor: 4.849